Nifedipine suppositories - RDD Pharma

Drug Profile

Nifedipine suppositories - RDD Pharma

Alternative Names: Capository™; Coated Nifedipine Suppositories - RDD Pharma; Nifedipine coated suppositories - RDD Pharma; RDD-1219

Latest Information Update: 24 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator RDD Pharma
  • Class Antihypertensives; Dihydropyridines; Heart failure therapies; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Fissure in ano

Most Recent Events

  • 21 Feb 2017 RDD Pharma has patent protection for RDD 1219 in USA, Israel and the EU
  • 01 May 2016 Phase-II/III clinical trials in Fissure in ano (Adjunctive treatment) in Bulgaria (Rectal) (NCT02527109)
  • 01 Nov 2015 RDD Pharma terminates a phase I/II trial for Fissure in ano in Israel (NCT02023047)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top